Stock Price, News, Quote and Profile of MAINZ BIOMED NV(NASDAQ:MYNZ) stock

MAINZ BIOMED NV

NASDAQ:MYNZ (12/24/2024, 7:27:25 PM)

After market: 5.13 +0.31 (+6.43%)

4.82

-0.14 (-2.82%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-3487.15%

Sales Q2Q%109.99%

CRS1.56

6 Month-69.95%

Overview

Earnings (Last)11-11 2024-11-11/bmo

Earnings (Next)N/A N/A

Ins Owners16.54%

Inst Owners0.47%

Market Cap9.21M

Shares1.91M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts45.71

Short Float %N/A

Short Ratio1

IPO11-04 2021-11-04

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 65 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Company Info

MAINZ BIOMED NV

Sirius Gutenberg Park, Robert-Koch-Strasse 50

MAINZ HESSEN

P: 4961315542860

Employees: 68

Website: https://www.mainzbiomed.com/

MYNZ News

2 days ago - ChartmillMonday's session: top gainers and losers

Let's take a look at the stocks that are in motion in today's session.

2 days ago - ChartmillWhat's going on in today's session

These stocks are moving in today's session

5 days ago - ChartmillHere are the top movers in Friday's session, showcasing the stocks with significant price changes.

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.